North America Genetic Testing Market Forecast 2022-2030
Description
North America Genetic Testing Market Forecast 2022-2030
KEY FINDINGS
The North America genetic testing market is predicted to register a CAGR of 10.43% during the forecast period, 2022-2030. The high rates of diseases and disorders offer growth opportunities. For instance, obesity is high in North America. Also, cancer is the second-leading cause of death in the US and the foremost cause in Canada. In addition, as per the latest stats, around 693,000 cancer deaths and almost 1.9 million new cancer cases were recorded in North America.
MARKET INSIGHTS
Canada and the United States are evaluated for the North America genetic testing market growth analysis. Canada offers free healthcare to citizens. The total healthcare expenditure in the country was almost $308 billion in 2021. It also constituted 12.7% of Canada’s gross domestic product. Also, the pandemic has raised the tendency to opt for genetic testing. This is because diabetes patients were more liable to become coronavirus casualties.
In addition, Canadian researchers have developed a new genetic test that gives a precise prediction of the prostate cancer risk post-treatment. Besides, this test uses the genomic profile of the tumor and oxygen content of the area around the tumor to determine relapse risks. Such factors are favorable to market growth.
COMPETITIVE INSIGHTS
Some of the key market players include Myriad Genetics Inc, Qiagen, Luminex Corporation, PerkinElmer Inc, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
KEY FINDINGS
The North America genetic testing market is predicted to register a CAGR of 10.43% during the forecast period, 2022-2030. The high rates of diseases and disorders offer growth opportunities. For instance, obesity is high in North America. Also, cancer is the second-leading cause of death in the US and the foremost cause in Canada. In addition, as per the latest stats, around 693,000 cancer deaths and almost 1.9 million new cancer cases were recorded in North America.
MARKET INSIGHTS
Canada and the United States are evaluated for the North America genetic testing market growth analysis. Canada offers free healthcare to citizens. The total healthcare expenditure in the country was almost $308 billion in 2021. It also constituted 12.7% of Canada’s gross domestic product. Also, the pandemic has raised the tendency to opt for genetic testing. This is because diabetes patients were more liable to become coronavirus casualties.
In addition, Canadian researchers have developed a new genetic test that gives a precise prediction of the prostate cancer risk post-treatment. Besides, this test uses the genomic profile of the tumor and oxygen content of the area around the tumor to determine relapse risks. Such factors are favorable to market growth.
COMPETITIVE INSIGHTS
Some of the key market players include Myriad Genetics Inc, Qiagen, Luminex Corporation, PerkinElmer Inc, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
163 Pages
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Advancements In Biotechnology
- 3.1.2. Growth In Prenatal Testing
- 3.1.3. Rise In Direct-to-consumer Genetic Testing
- 3.1.4. Genetic Testing Helps In Determining Medication Dosage
- 3.2. Key Restraints
- 3.2.1. Expensive Cost Of Treatment
- 3.2.2. Government Regulation And Legislation
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Genetic Testing Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Vendor Landscape
- 4.6. Value Chain Analysis
- 4.7. Key Buying Criteria
- 4.8. Regulatory Framework
- 5. Market By Type
- 5.1. Prenatal And Newborn Testing
- 5.2. Diagnostic Testing
- 5.3. Predictive & Presymptomatic Testing
- 5.4. Carrier Testing
- 5.5. Pharmacogenomic Testing
- 5.6. Other Types
- 6. Market By Technology
- 6.1. Molecular Testing
- 6.2. Cytogenetic Testing
- 6.3. Biochemical Testing
- 7. Market By Application
- 7.1. Genetic Disease Diagnosis
- 7.2. Cancer Diagnosis
- 7.3. Cardiovascular Disease Diagnosis
- 7.4. Other Applications
- 8. Market By Disease
- 8.1. Cancer
- 8.2. Cystic Fibrosis
- 8.3. Huntington’s Disease
- 8.4. Sickle Cell Anaemia
- 8.5. Duchenne Muscular Dystrophy
- 8.6. Alzheimer’s Disease
- 8.7. Rare Diseases
- 8.8. Thalassemia
- 8.9. Other Diseases
- 9. Geographical Analysis
- 9.1. North America
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Growth Enablers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. United States
- 9.1.5.2. Canada
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.1.4. Business Expansions & Divestitures
- 10.2. Company Profiles
- 10.2.1. 23&Me Inc
- 10.2.2. Abbott Laboratories
- 10.2.3. Bgi Group
- 10.2.4. Bio-rad Laboratories
- 10.2.5. Csl Limited
- 10.2.6. Decode Genetics
- 10.2.7. Elitech Group
- 10.2.8. Eurofins Scientific
- 10.2.9. Illumina Inc
- 10.2.10. Luminex Corporation
- 10.2.11. Myriad Genetics Inc
- 10.2.12. Perkinelmer Inc
- 10.2.13. Qiagen
- 10.2.14. Quest Diagnostics Inc
- 10.2.15. Roche Diagnostics Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
